Figures and comparison tables of GLP-1RAs provide valuable insights into dosing frequency, main use, weight loss efficacy, and blood sugar control, assisting healthcare professionals and patients in choosing the most appropriate treatment based on therapeutic goals and individual needs
Phase III trials were carried out as part of the SURPASS programme to investigate its therapeutic effectiveness (glycaemic control and body weight reduction) and safety/tolerability for the treatment of patients with type 2 diabetes [90, 91]
2024, StatPearls Publishing, 2025 Jan
Proteins were on-bead digested overnight in a solution containing LysC and trypsin at 37 C
the interaction with growth hormone secretagogues, which may raise glucose, is unpredictable Cardiovascular effects increased heart rate has been observed with GLP-1-based therapies